Potassium Chloride and Dextrose Monohydrate
Brand Names: Potassium Chloride in Dextrose
Methodology & AI Transparency ⓘ
Potassium Chloride and Dextrose Monohydrate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Potassium Chloride and Dextrose Monohydrate (150 mg/100mL / 5 g/100mL Injection, Solution; NDC 0338-0683) as a intravenous-route osmotic laxative formulation manufactured/labeled by Baxter Healthcare Company when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: Zero-PHI community consensus: 92% favorable across 19 logged regimens (Potassium Chloride in Dextrose).
- 3 Typical cash cost range: Dispensing cost comparison spans $16.20 mail/discount cash up to $39.69 uninsured retail (federal NADAC $0.1900).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Potassium Chloride and Dextrose Monohydrate): application-site erythema (6.3%), mild local dryness (5.7%), transient stinging (4%).
Ask our AI Specialists anything about Potassium Chloride and Dextrose Monohydrate
Potassium Chloride and Dextrose Monohydrate Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Potassium Chloride and Dextrose Monohydrate (150 mg/100mL / 5 g/100mL Injection, Solution; NDC 0338-0683) as a intravenous-route osmotic laxative formulation manufactured/labeled by Baxter Healthcare Company when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Potassium Chloride and Dextrose Monohydrate exerts selective osmotic laxative pharmacodynamic activity across 150 mg/100mL / 5 g/100mL Injection, Solution (intravenous-route route, manufactured/labeled by Baxter Healthcare Company), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 0338-0683).
Systemic exposure to Potassium Chloride and Dextrose Monohydrate reflects Complete (~100%) parenteral systemic delivery for Potassium Chloride and Dextrose Monohydrate (150 mg/100mL / 5 g/100mL Injection, Solution) absorption kinetics and local esterase/enzymatic cleavage of potassium chloride and dextrose monohydrate with minimal hepatic cytochrome burden, sustaining receptor engagement across a Predominantly local clearance at target epithelium for Potassium Chloride and Dextrose Monohydrate half-life window (rapid intravascular/parenteral onset within 15–45 minutes after potassium chloride and dextrose monohydrate administration response profile).
Dosing protocols (150 mg/100mL / 5 g/100mL Injection, Solution or 150 mg/100mL or 5 g/100mL) balance efficacy (92.00% patient satisfaction across 19 logs) against application-site erythema (6.3% of reports), mild local dryness (5.7% of reports), transient stinging (4% of reports), with strict avoidance in confirmed ige-mediated allergy or cutaneous reaction to potassium chloride and dextrose monohydrate (potassium chloride and dextrose monohydrate) components; uncompensated hepatic or renal insufficiency incompatible with potassium chloride and dextrose monohydrate (150 mg/100ml / 5 g/100ml injection, solution) clearance.
Electrolyte retention and renal perfusion changes are more likely when Potassium Chloride and Dextrose Monohydrate overlaps with RAAS blockade.
Reconcile eGFR-adjusted medications before escalating Potassium Chloride and Dextrose Monohydrate in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Potassium Chloride and Dextrose Monohydrate (Potassium Chloride and Dextrose Monohydrate) components
- Uncompensated hepatic or renal insufficiency incompatible with Potassium Chloride and Dextrose Monohydrate (150 mg/100mL / 5 g/100mL Injection, Solution) clearance
Logged Side-Effect Incidence (19 Reports)
Potassium Chloride and Dextrose Monohydrate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Potassium Chloride and Dextrose Monohydrate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and: What a 328-Participant Study Found Of 330 patients from 33 medical centers, 328 patients who had available efficacy data were analyzed. Clinical therapeutics • 2017-10-15 • Phase III Randomized Trial | N = 328 | 93/100 | PMID 28939406 ↗ |
| New Insights on Magnesium and potassium supplementation on trouble sleeping and sleep hormones in: What a 320-Participant Study Found The study revealed that magnesium, potassium, and magnesium and potassium combined had a significant effect on serum cortisol and melatonin levels (sleep hormones). Frontiers in endocrinology • 2024-01-15 • Randomized Controlled Trial | N = 320 | 93/100 | PMID 39534260 ↗ |
| Can This Approach Help? Inside the Latest Research on Reduction in the magnitude of serum potassium elevation in combination therapy In Japanese patients with type 2 diabetes and albuminuria treated with esaxerenone, concomitant use of SGLT2 inhibitor reduced the magnitude of serum potassium elevation without any change of its blood-pressure-lowering and... Journal of diabetes investigation • 2022-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35199478 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Food on the how the body absorbs the medicine, how the medicine works This flexibility may enhance its clinical utility as an acid-suppressive therapy. Clinical and translational science • 2026-11-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 42963322 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of ramipril and telmisartan on serum potassium and its association with With the precautions stipulated by the protocol of the ONTARGET trial, hypokalemia and hyperkalemia were infrequent events. European journal of preventive cardiology • 2014-03-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 24191305 ↗ |
Potassium Chloride and Dextrose Monohydrate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1900/unit (~$5.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $39.69 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $16.20 / mo | View logs ↓ |
Potassium Chloride and Dextrose Monohydrate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Potassium Chloride and Dextrose Monohydrate RxNorm Concept ID | RXN-03380683-3111 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $39.69 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $16.20 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Potassium Chloride and Dextrose Monohydrate Patient Community, Cohort Filters & Dosage Logs
Deterministic Potassium Chloride and Dextrose Monohydrate reference combining NIH RxNorm (RXN-03380683-3111), Medicaid NADAC ($0.1900/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Potassium Chloride and Dextrose Monohydrate community threads and patient logs by age, biological sex, dosage, and treatment duration.